RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) – Analysts at Cantor Fitzgerald boosted their FY2022 earnings per share estimates for shares of RAPT Therapeutics in a research note issued on Tuesday, May 24th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings of ($3.19) per share for the year, up from their prior estimate of ($3.31). Cantor Fitzgerald currently has a “Overweight” rating on the stock.

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.01). RAPT Therapeutics had a negative net margin of 2,263.55% and a negative return on equity of 37.82%.

Several other equities research analysts also recently weighed in on RAPT. Piper Sandler cut their target price on shares of RAPT Therapeutics from $52.00 to $30.00 in a research note on Thursday, May 12th. HC Wainwright reissued a “buy” rating and issued a $56.00 price objective on shares of RAPT Therapeutics in a research report on Monday, March 14th. Wells Fargo & Company lowered their target price on shares of RAPT Therapeutics from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, March 11th. Finally, Roth Capital restated a “buy” rating on shares of RAPT Therapeutics in a report on Wednesday, March 16th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $52.25.

Shares of RAPT opened at $13.64 on Thursday. RAPT Therapeutics has a fifty-two week low of $9.85 and a fifty-two week high of $43.26. The firm’s 50 day moving average price is $18.20 and its 200 day moving average price is $24.69. The company has a market cap of $404.34 million, a P/E ratio of -5.33 and a beta of 0.99.

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada raised its position in RAPT Therapeutics by 89.2% during the 2nd quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock worth $39,000 after buying an additional 580 shares during the last quarter. Citigroup Inc. raised its position in RAPT Therapeutics by 58.4% during the 3rd quarter. Citigroup Inc. now owns 4,298 shares of the company’s stock worth $133,000 after buying an additional 1,584 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in RAPT Therapeutics during the 4th quarter worth $159,000. Dupont Capital Management Corp purchased a new position in shares of RAPT Therapeutics in the 4th quarter valued at about $209,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of RAPT Therapeutics in the 4th quarter valued at about $223,000. Institutional investors own 95.22% of the company’s stock.

In other RAPT Therapeutics news, major shareholder Group Ii Lp Column purchased 1,250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average price of $10.67 per share, for a total transaction of $13,337,500.00. Following the purchase, the insider now directly owns 1,208,750 shares in the company, valued at $12,897,362.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dirk G. Brockstedt sold 2,648 shares of the stock in a transaction on Friday, March 11th. The stock was sold at an average price of $23.91, for a total transaction of $63,313.68. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 1,269,736 shares of company stock valued at $13,568,680 and have sold 12,015 shares valued at $260,413. 5.00% of the stock is owned by corporate insiders.

About RAPT Therapeutics (Get Rating)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Featured Articles

Receive News & Ratings for RAPT Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for RAPT Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.